Researchers suggest a less traditional assessment could help flag dementia earlier

2019 ended on a high note for Alzheimer’s research.

Just before the new year, the pharma company Biogen released clinical trial data suggesting that its drug, aducanumab, could successfully remove amyloid from the brain—one of the trademark proteins behind Alzheimer’s disease.

  • Kathleen Ellen Foley
  • Quartz

Understandably, the drug has gotten a lot of attention: It’s been a bleak few decades for Alzheimer’s research, whose history is …

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button